Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people begin to lose weight on Wegovy within the first two to four weeks, though the amount at that stage is modest. In the STEP 1 clinical trial, participants lost an average of around 15% of their body weight over 68 weeks at the 2.4mg maintenance dose — the meaningful losses build gradually as the dose increases and appetite suppression deepens. Wegovy (semaglutide) is a prescription-only medicine, so a prescriber assesses whether it is clinically suitable for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the scene: you've started Wegovy, the pen is sitting in the fridge door, and you're wondering when something is going to happen. For most people, the first thing that changes is appetite, not weight. The starter dose (0.25mg) is designed to let your body adjust, not to produce dramatic losses. Nausea is common at this point, and food often becomes less appealing simply because larger portions feel uncomfortable. That matters, because eating less is exactly the mechanism through which semaglutide helps with weight.
For a closer look at the very early experience, our page on what happens in the first weeks after starting Wegovy walks through it in more detail. By week four, many people have shed a small amount (often one to three kilograms) though this varies considerably depending on starting weight, diet and activity.
One thing our prescribers hear frequently: people who expect dramatic week-one results feel disappointed, then notice at the six-week mark that their clothes fit differently. If you're curious about how soon you start losing weight on Wegovy, the honest answer is that the appetite change is real, but it takes time to translate into visible loss.
The titration schedule moves dose upward roughly every four weeks: from 0.25mg to 0.5mg, then 1mg, 1.7mg, and finally 2.4mg. At each step, appetite suppression typically deepens. This is why the weight loss curve for Wegovy is not a straight line, it tends to steepen through the middle months as higher doses take hold.
By the time someone reaches 2.4mg maintenance, they are usually around five months into treatment. Many people in the STEP 1 trial had lost around 8 to 10% of their starting body weight by the halfway point, with losses continuing through to the 68-week mark. For context on how quickly weight loss progresses, the pattern is fairly consistent: slow and uncertain early, then more noticeable through months two to six, then gradual and steadier toward the end.
What you eat, how active you are, and how well you tolerate each dose step all influence the pace. The NHS medicines page for semaglutide explains that side effects like nausea and vomiting are most likely after starting or increasing the dose, managing these well tends to support better adherence, and adherence shapes results.
The headline figure from STEP 1 is an average of approximately 15% body-weight reduction over 68 weeks. That is a meaningful number. But averages smooth over a wide spread: some participants lost considerably more, others less. A person's starting BMI, metabolic profile and how consistently they use the treatment all affect where they land.
There is also the newer 7.2mg dose to consider. The MHRA approved a dedicated single-dose 7.2mg pen on 14 April 2026; early evidence suggests average losses of around 20.7% over 72 weeks at this higher dose, approaching what has been seen with tirzepatide at its highest strength. If you want to understand the full semaglutide picture (including how semaglutide works across its licensed doses) that context is worth reading before your consultation.
No trial result tells you exactly what will happen to you. A prescriber can give you a more personalised expectation based on your health history, and that conversation is where the real planning happens.
Some things that influence how soon and how much weight shifts are within reach: prioritising protein at each meal helps preserve muscle while in a calorie deficit; staying well hydrated supports GI tolerance; consistent activity (even walking) contributes meaningfully over months. Our page on getting the most from Wegovy goes into practical habits that complement the medicine.
Some things are not controllable, genetics, hormonal factors, the rate at which the GI side effects settle. Weight is a health condition shaped by biology, not simply a matter of effort.
On cost: treatment like this is an investment, and it's fair to understand what you're paying for. The Wegovy pricing page sets out what a legitimate private prescription typically includes, one transparent price, no subscription, no surprise fees.
If you'd like to speak with a clinician about whether Wegovy is right for you and what a realistic timeline might look like for your circumstances, our team reviews consultations the same day. Prescriptions are written by a real clinician, not generated by software, and treatment is dispatched the same working day if clinically approved, arriving the next working day in plain, unbranded packaging via DPD, with a tracking link sent to your phone. Speak to our prescribers when you're ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.